Condition: Pulmonary Hypertension · Right Ventricular Dysfunction · Right Heart Failure · Sponsor: University of Alberta
The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.
This description comes directly from the study's public registry record.
Jason Weatherald, MD,MSc,FRCPC · 780-492-9937 · weathera@ualberta.ca
Courtney Gubbels, BA · 780-492-1113 · courtney.gubbels@ualberta.ca
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Not Yet Recruiting |
| University of Alberta | Edmonton, Alberta, Canada | Recruiting |
| The University of British Columbia | Vancouver, British Columbia, Canada | Not Yet Recruiting |
| London Health Sciences Centre - University Hospital | London, Ontario, Canada | Not Yet Recruiting |
| The Ottawa Hospital | Ottawa, Ontario, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06570473